Published in Fibrogenesis Tissue Repair on February 17, 2010
The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol (2010) 2.07
Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling. PLoS One (2014) 1.48
Functional roles and clinical values of insulin-like growth factor-binding protein-5 in different types of cancers. Chin J Cancer (2012) 1.01
Membrane-to-nucleus signaling links insulin-like growth factor-1- and stem cell factor-activated pathways. PLoS One (2013) 0.85
Insulin-like growth factor system in cancer: novel targeted therapies. Biomed Res Int (2015) 0.84
Herbal compound "Songyou Yin" attenuates hepatoma cell invasiveness and metastasis through downregulation of cytokines secreted by activated hepatic stellate cells. BMC Complement Altern Med (2013) 0.82
Critical role of insulin‑like growth factor binding protein‑5 in methamphetamine‑induced apoptosis in cardiomyocytes. Mol Med Rep (2014) 0.79
Insulin-like growth factor binding proteins-3 and -5: central mediators of fibrosis and promising new therapeutic targets. Open Rheumatol J (2012) 0.78
The herbal compound Songyou Yin (SYY) inhibits hepatocellular carcinoma growth and improves survival in models of chronic fibrosis via paracrine inhibition of activated hepatic stellate cells. Oncotarget (2015) 0.78
Activated hepatic stellate cells play pivotal roles in hepatocellular carcinoma cell chemoresistance and migration in multicellular tumor spheroids. Sci Rep (2016) 0.75
Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett (2003) 18.34
Cellular and molecular mechanisms of fibrosis. J Pathol (2008) 14.01
Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev (1995) 9.54
Senescence of activated stellate cells limits liver fibrosis. Cell (2008) 8.98
Liver fibrosis -- from bench to bedside. J Hepatol (2003) 5.80
Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut (2005) 5.39
Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis (2001) 2.42
Hepatic stellate cell behavior during resolution of liver injury. Semin Liver Dis (2001) 2.32
Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol (1994) 2.26
Perisinusoidal stellate cells of the liver: important roles in retinol metabolism and fibrosis. FASEB J (1991) 2.22
Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. Hepatology (1999) 2.07
Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. Am J Pathol (2005) 1.91
Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis. Biochem J (2006) 1.77
Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol (2005) 1.62
Growth factors in idiopathic pulmonary fibrosis: relative roles. Respir Res (2001) 1.55
IGF-binding protein-5: flexible player in the IGF system and effector on its own. J Endocrinol (2002) 1.45
Lentiviral vectors for efficient transduction of isolated primary quiescent hepatocytes. J Hepatol (2002) 1.43
Proteasome inhibition induces hepatic stellate cell apoptosis. Hepatology (2006) 1.42
Induction of cellular senescence by insulin-like growth factor binding protein-5 through a p53-dependent mechanism. Mol Biol Cell (2007) 1.38
The IGF axis and programmed cell death. Immunol Cell Biol (1999) 1.33
PDGF-mediated chemoattraction of hepatic stellate cells by bile duct segments in cholestatic liver injury. Lab Invest (2000) 1.32
Transcriptional profiling reveals novel markers of liver fibrogenesis: gremlin and insulin-like growth factor-binding proteins. J Biol Chem (2006) 1.25
Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. Hepatology (2005) 1.25
Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J Hepatol (2005) 1.23
Partitioning of IGFBP-5 actions in myogenesis: IGF-independent anti-apoptotic function. J Cell Sci (2004) 1.20
In vitro migratory potential of rat quiescent hepatic stellate cells and its augmentation by cell activation. Hepatology (1999) 1.17
Insulin-like growth factor-binding protein-5 induces pulmonary fibrosis and triggers mononuclear cellular infiltration. Am J Pathol (2006) 1.17
Effects of Ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene. Gastroenterology (1996) 1.13
Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3'-kinase pathway. Endocrinology (2000) 1.13
Differential IGF-independent effects of insulin-like growth factor binding proteins (1-6) on apoptosis of breast epithelial cells. J Cell Biochem (1999) 1.11
Insulin-like growth factor binding protein 5 induces skin fibrosis: A novel murine model for dermal fibrosis. Arthritis Rheum (2006) 1.09
Hypoxia induces the activation of human hepatic stellate cells LX-2 through TGF-beta signaling pathway. FEBS Lett (2006) 1.06
Intrinsic actions of IGFBP-3 and IGFBP-5 on Hs578T breast cancer epithelial cells: inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin. J Cell Sci (2002) 1.06
Liver fibrosis: perspectives in pathobiochemical research and clinical outlook. Eur J Clin Chem Clin Biochem (1991) 1.05
Association of gankyrin protein expression with early clinical stages and insulin-like growth factor-binding protein 5 expression in human hepatocellular carcinoma. Hepatology (2008) 1.04
Insulin-like growth factor (IGF)-binding protein 5 forms an alternative ternary complex with IGFs and the acid-labile subunit. J Biol Chem (1998) 1.03
Gliotoxin non-selectively induces apoptosis in fibrotic and normal livers. Liver Int (2006) 1.02
Insulin-like growth factor binding protein-5 influences pancreatic cancer cell growth. World J Gastroenterol (2009) 1.00
Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma. J Hepatol (2008) 1.00
Insulin-like growth factor-binding protein-5 (IGFBP-5) stimulates phosphorylation of the IGFBP-5 receptor. Am J Physiol (1998) 0.99
Epithelial injury induces an innate repair mechanism linked to cellular senescence and fibrosis involving IGF-binding protein-5. J Endocrinol (2008) 0.98
Delayed mammary gland involution in mice with mutation of the insulin-like growth factor binding protein 5 gene. Endocrinology (2007) 0.95
Insulin-like growth factor-I serum concentrations and patterns of insulin-like growth factor binding proteins in patients with chronic liver disease. J Hepatol (1996) 0.94
Tumor necrosis factor-alpha-induced apoptosis is associated with suppression of insulin-like growth factor binding protein-5 secretion in differentiating murine skeletal myoblasts. J Cell Physiol (2000) 0.93
Differential insulin-like growth factor (IGF)-independent interactions of IGF binding protein-3 and IGF binding protein-5 on apoptosis in human breast cancer cells. Involvement of the mitochondria. J Cell Biochem (2000) 0.91
Characterization and regulation of insulin-like growth factor binding proteins in human hepatic stellate cells. J Cell Physiol (1998) 0.88
Heparin modulates the binding of insulin-like growth factor (IGF) binding protein-5 to a membrane protein in osteoblastic cells. J Biol Chem (1995) 0.88
Insulin-like growth factor binding protein (IGFBP)-5 is upregulated during both differentiation and apoptosis in primary cultures of mouse mammary epithelial cells. J Cell Physiol (2006) 0.87
Insulin-like growth factor binding protein-5 (IGFBP-5) potentially regulates programmed cell death and plasminogen activation in the mammary gland. Adv Exp Med Biol (2000) 0.86
Expression of thyroid hormone receptors A and B in developing rat tissues; evidence for extensive posttranscriptional regulation. J Mol Endocrinol (2007) 0.83
Role of insulin-like growth factor binding proteins in modifying IGF actions. Ann N Y Acad Sci (1993) 0.82
Insulin-like growth factor binding proteins initiate cell death and extracellular matrix remodeling in the mammary gland. Domest Anim Endocrinol (2005) 0.81
Insulin-like growth factor binding protein-5 enhances the migration and differentiation of gingival epithelial cells. J Periodontal Res (2008) 0.79
Comparison studies of IGFBP-5 binding to osteoblasts and osteoblast-derived extracellular matrix. Prog Growth Factor Res (1995) 0.79
Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology (2002) 2.19
Starvation induces phase-specific changes in the proteome of mouse small intestine. J Proteome Res (2006) 1.54
Induction of insolubility by herpes simplex virus VP22 precludes intercellular trafficking of N-terminal Apoptin-VP22 fusion proteins. J Mol Med (Berl) (2003) 1.44
Increased formation of pyridinoline cross-links due to higher telopeptide lysyl hydroxylase levels is a general fibrotic phenomenon. Matrix Biol (2004) 1.16
Anion exchanger 2 is essential for spermiogenesis in mice. Proc Natl Acad Sci U S A (2003) 1.11
Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice. Hepatology (2009) 1.09
Interorgan coordination of the murine adaptive response to fasting. J Biol Chem (2011) 0.93
Crigler-Najjar syndrome in The Netherlands: identification of four novel UGT1A1 alleles, genotype-phenotype correlation, and functional analysis of 10 missense mutants. Hum Mutat (2010) 0.91
Ex-vivo evaluation of gene therapy vectors in human pancreatic (cancer) tissue slices. World J Gastroenterol (2009) 0.90
Novel immortalized human fetal liver cell line, cBAL111, has the potential to differentiate into functional hepatocytes. BMC Biotechnol (2009) 0.87
Ephrin A2 receptor targeting does not increase adenoviral pancreatic cancer transduction in vivo. World J Gastroenterol (2009) 0.84
Polyinosinic acid blocks adeno-associated virus macrophage endocytosis in vitro and enhances adeno-associated virus liver-directed gene therapy in vivo. Hum Gene Ther (2013) 0.83
Mycophenolate mofetil impairs transduction of single-stranded adeno-associated viral vectors. Hum Gene Ther (2011) 0.82
A genetically retargeted adenoviral vector enhances viral transduction in esophageal carcinoma cell lines and primary cultured esophageal resection specimens. Ann Surg (2003) 0.82
A fiber modified adenovirus vector that targets to the EphrinA2 receptor reveals enhanced gene transfer to ex vivo pancreatic cancer. Int J Oncol (2010) 0.82
Towards liver-directed gene therapy for Crigler-Najjar syndrome. Curr Gene Ther (2009) 0.81
Fasting reduces liver fibrosis in a mouse model for chronic cholangiopathies. Biochim Biophys Acta (2013) 0.81
Adenoviral serotypes in gene therapy for esophageal carcinoma. J Surg Res (2007) 0.79
Gene therapy for esophageal carcinoma: the use of an explant model to test adenoviral vectors ex vivo. Cancer Gene Ther (2004) 0.78
Insulin-like growth factor 1 enhances bile-duct proliferation and fibrosis in Abcb4(-/-) mice. Biochim Biophys Acta (2013) 0.78
Selection of tumour specific promoters for adenoviral gene therapy of cholangiocarcinoma. J Hepatol (2005) 0.77
Gene therapy for barrett's esophagus: adenoviral gene transfer in different intestinal models. Cancer Gene Ther (2005) 0.76
ATP8B1 and ATP11C: Two Lipid Flippases Important for Hepatocyte Function. Dig Dis (2015) 0.75
The current state of cancer gene therapy and its application in esophageal carcinoma. Dig Surg (2005) 0.75
Overexpression of insulin like growth factor binding protein 5 reduces liver fibrosis in chronic cholangiopathy. Biochim Biophys Acta (2012) 0.75
Gene replacement therapy for genetic hepatocellular jaundice. Clin Rev Allergy Immunol (2015) 0.75
Crigler-Najjar syndrome type 1 associated with combined 1070A-->G, Q357R and (TA)7 mutation in Kuwaiti Bedouin families indicate a founder effect in Arabs. J Clin Gastroenterol (2004) 0.75
Ezetimibe: A biomarker for efficacy of liver directed UGT1A1 gene therapy for inherited hyperbilirubinemia. Biochim Biophys Acta (2012) 0.75
Loss of heterozygosity and immunohistochemistry of adenocarcinomas of the esophagus and gastric cardia. Clin Cancer Res (2004) 0.75